A preliminary evaluation of a combination of interferon alpha and cis-retinoic acid in patients with certain vascular tumors-malignant and benign (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

A preliminary evaluation of a combination of interferon alpha and cis-retinoic acid in patients with certain vascular tumors-malignant and benign (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 15:A1695 1996. Unique Identifier : AIDSLINE ICDB/97636695
Burgess MA; Patel SR; Plager C; Raney RB Jr; Benjamin RS; UT M.D. Anderson Cancer Center, Houston, TX 77030

Abstract: Based upon the antiangiogenic properties of both interferon-alpha (IFN-a) and 13-cis-retinoic acid (CRA), together with the effectiveness of IFN-a against benign (capillary hemangiomas of infancy) and malignant (HIV-related Kaposi's sarcoma) vascular lesions, a combination of IFN-a and CRA was used to treat 16 patients (pts) with various tumors of vascular origin. Pts with the following diagnoses were treated: angiosarcoma (AS) of the head and neck (5 pts), breast (1 pt), and heart (1 pt), hemangiopericytoma (HP) (4 pts), epithelioid hemangioendothelioma (E HE) (1 pt), and benign hemangiomas (3 pts). The median age was 51 (range 12-80) and there were 10 males. All pts were good performance status and 3 pts had received prior chemotherapy or XRT. The dosages were IFN-a, 6 x 10(6) IU sc daily and CRA 1 mg/kg po in two divided doses. The clinical results are tabulated in a table. Eleven pts received treatment for 2 months or more. Four pts (AS-2 pts, HP-2 pts) were discontinued after one month because of progressive disease. Two pts with minimal disease AS of the face manifest brief clinical responses, and two pts with AS of the head had stable disease for 4 and 12 mo. A pt with hemangioma had relief of pain and radiologic improvement for greater than 12 mo. The drugs were tolerated poorly by elderly pts, the major side-effects being chronic fatigue and cheilitis. Myelosuppression was modest and uncomplicated. The clinical activity in AS of the head and neck is being pursued. Additional experience in pts with the more indolent HP, EHE and benign hemangiomas should be acquired.

Keywords: Adolescence Adult Aged Child Drug Therapy, Combination Female Hemangioendothelioma/DRUG THERAPY Hemangioma/DRUG THERAPY Hemangiopericytoma/DRUG THERAPY Hemangiosarcoma/DRUG THERAPY Human Interferon-alpha/*ADMINISTRATION & DOSAGE Isotretinoin/*ADMINISTRATION & DOSAGE Male Middle Age ABSTRACT
970330
M9731525

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .